- Achieve Life Sciences (ACHV) is a $685 million biotech focused on cytisinicline-based nicotine addiction treatments, showing strong recent technical momentum.
- ACHV has surged 173% over 52 weeks.
- Shares recently hit a 3-year high earlier in July.
- Despite robust technicals, ACHV remains highly speculative, as it has not yet begun monetizing its research pipeline.
Today’s Featured Stock
Valued at $685 million, Achieve Life Sciences (ACHV) is a pharmaceutical company. It develops and commercializes cytisinicline treatment to help people battling nicotine addiction.
What I’m Watching
I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals and superior current momentum. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. ACHV checks those boxes. The Trend Seeker issued a new “Buy” signal on June 25. Since then, the stock has gained 16.84%.
Barchart’s Technical Indicators for Achieve Life Sciences
Editor’s Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.
Achieve Life Sciences scored a 3-year high of $7.11 on July 1.
- Achieve Life Sciences has a Weighted Alpha of 122.15.
- ACHV has a 100% “Buy” opinion from Barchart.
- The stock has gained 173.36% over the past 52 weeks.
- Achieve Life Sciences has its Trend Seeker “Buy” signal intact.
- The stock recently traded at $6.62 with a 50-day moving average of $6.
- ACHV has made 13 new highs and gained 9.17% over the past month.
- 60-month beta of 2.24.
- Relative Strength Index (RSI) is at 58.74.
- There’s a technical support level around $6.55.
Don’t Forget the Fundamentals
- $685 million market capitalization.
- The company has yet to begin monetizing its research.
Analyst and Investor Sentiment on Achieve Life Sciences
- The Wall Street analysts followed by Barchart give the stock 8 “Strong Buy” opinions with price targets between $10 and $21.
- Value Line does not rate the stock.
- CFRA’s MarketScope rates the stock a “Sell.”
- Morningstar thinks the stock is 8% undervalued with a fair value of $7.28.
- 7,820 investors are following the stock on Seeking Alpha, which rates it a “Hold.”
- Short interest is 14.35% of the float with 7.77 days to cover the float.
The Bottom Line on Achieve Life Sciences
ACHV is highly speculative. Based on analysts’ predictions, it may begin to monetize its research soon.
Additional disclosure: The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance.
On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.